Core Insights - Abeona Therapeutics has completed its first commercial patient treatment of ZEVASKYN in December 2025, with plans to build momentum for its launch in the first quarter of 2026 [1][7] - The company reported total revenue of $5.8 million for the year ended December 31, 2025, which includes $3.4 million in license and other revenues and $2.4 million in net product revenue [3][9] - Abeona's net income for 2025 was $71.2 million, a significant turnaround from a net loss of $63.7 million in 2024 [9][14] Financial Performance - Total revenue for 2025 was $5.8 million, consisting of $2.4 million in net product revenue and $3.4 million in license and other revenues [3][14] - Cost of sales for 2025 was $1.5 million, primarily due to the first commercial treatment of ZEVASKYN and production costs from an August batch that faced technical challenges [5][14] - Research and development (R&D) spending decreased to $26.8 million in 2025 from $34.4 million in 2024, attributed to the FDA approval of ZEVASKYN [6][14] - Selling, general and administrative (SG&A) expenses rose to $65.0 million in 2025, an increase of $35.1 million over 2024, reflecting the company's commercial transition post-FDA approval [7][14] Operational Updates - The first ZEVASKYN treatment was completed in December 2025, with ongoing efforts to streamline the treatment process and expand patient access [1][4][7] - Abeona has activated The University of Texas Medical Branch (UTMB) as the fourth Qualified Treatment Center (QTC) for ZEVASKYN, enhancing patient access in Texas and the Gulf Coast region [7] - The company anticipates that positive patient experiences will drive sustained demand for ZEVASKYN within the recessive dystrophic epidermolysis bullosa (RDEB) community [7] Cash Position - As of December 31, 2025, Abeona reported cash, cash equivalents, and short-term investments totaling $191.4 million [1][9]

Core Insights - Abeona Therapeutics Inc. has launched ZEVASKYN, an FDA-approved autologous gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][10] Company Update - The commercial launch of ZEVASKYN began in Q4 2025, with the first patient treatment completed in December 2025 [2] - Manufacturing resumed in late January 2026, with multiple biopsies collected and ongoing treatment processes [2] - The company is establishing a regular schedule for biopsy collections, indicating increased patient engagement and interest in ZEVASKYN [3] Market Access and Payer Engagement - ZEVASKYN has received coverage from all major commercial payers, including United Healthcare, Cigna, Aetna, Anthem, and most Blue Cross Blue Shield plans, covering 80% of lives under commercial insurance [4] - The therapy has also secured coverage across all Medicaid programs, enhancing its market acceptance [4] - A permanent HCPCS J-code (J3389) for ZEVASKYN was established by CMS, effective January 1, 2026, facilitating medical billing and reimbursement processes [4] Product Information - ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, addressing a severe skin condition caused by defects in the COL7A1 gene [6][7] - The therapy incorporates the COL7A1 gene into a patient's skin cells to produce functional type VII collagen, which is crucial for skin integrity [6] - Clinical results have shown meaningful wound healing and pain reduction with a single application of ZEVASKYN [6]

Core Viewpoint - Abeona Therapeutics Inc. is set to discuss its fourth quarter and full year 2025 financial results and corporate progress in a conference call on March 17, 2026 [1] Group 1: Conference Call Details - The conference call will take place at 8:30 a.m. ET and will be accessible via phone and webcast [1][2] - Participants can join the call by dialing 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) with Entry Code: 977217 [2] - A live webcast and archived replay will be available on the Investors & Media section of Abeona's website for 30 days following the call [2] Group 2: Upcoming Events - Abeona management will participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on March 10, 2026, at 8:40 a.m. ET [3] - The fireside chat will also be available via a live webcast and archived for 30 days on the company's website [3] Group 3: Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [4] - The company's ZEVASKYN is the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [4] - Abeona operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is used for ZEVASKYN's commercial production [4] - The company is also developing adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs [4]

Core Viewpoint - Abeona Therapeutics Inc. has appointed Mohamad Tabrizi as Senior Vice President and Chief Business Officer to enhance corporate strategy and business development efforts [1][2]. Group 1: Appointment and Role - Mohamad Tabrizi will lead the company's corporate strategy and business development functions, focusing on driving operational efficiency [1]. - Tabrizi has extensive experience in strategic planning and business development, which the company aims to leverage for optimizing operations and forming value-creating partnerships [2]. Group 2: Professional Background - Tabrizi previously worked in the venture capital sector as a General Partner and Managing Director at Pandect Bioventures and the Berkeley Catalyst Fund, where he led investment activities and operational roles [2]. - He has a strong track record in corporate development and capital markets, having executed 20 transactions at Nektar Therapeutics and led over 40 transactions as a healthcare investment banker, raising more than $5 billion [3]. Group 3: Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including its product ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa [4]. - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [4].

Core Insights - Abeona Therapeutics Inc. has activated The University of Texas Medical Branch (UTMB) as a Qualified Treatment Center (QTC) for ZEVASKYN, a gene-modified cellular therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][3] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being the first autologous cell-based gene therapy for RDEB [10] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [10] Product Information - ZEVASKYN (prademagene zamikeracel) is the first FDA-approved autologous gene therapy for RDEB, designed to treat chronic wounds by incorporating the COL7A1 gene into a patient's skin cells [5][6] - The therapy has shown clinically meaningful results in wound healing and pain reduction with a single surgical application [5] Treatment Center Activation - The activation of UTMB as a QTC significantly enhances patient access to ZEVASKYN across Texas and the Gulf Coast region, reflecting UTMB's commitment to innovative care [3] - UTMB is recognized for its expertise in complex skin diseases and wound care, making it an ideal partner for delivering ZEVASKYN [2][3] Patient Support Services - Abeona offers a comprehensive patient support program called Abeona Assist, which provides personalized assistance, including help with insurance benefits, financial options, and logistical support for patients [3]

Core Insights - Abeona Therapeutics Inc. has announced the first commercial patient treatment with its FDA-approved gene therapy ZEVASKYN, aimed at treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][2] - ZEVASKYN is the first and only autologous cell sheet-based gene therapy for RDEB, which is characterized by severe skin wounds due to a defect in the COL7A1 gene [4][5] - The treatment has shown clinically meaningful wound healing and pain reduction with a single surgical application [4] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being a key product in its portfolio [8] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [8] Treatment Details - ZEVASKYN incorporates the COL7A1 gene into a patient's skin cells to produce functional type VII collagen, essential for skin integrity [4] - The therapy is indicated for both adult and pediatric patients suffering from RDEB [5] - Abeona Assist® is a comprehensive patient support program that helps patients understand insurance benefits and provides logistical assistance [2]

Core Insights - Abeona Therapeutics Inc. reported financial results and operational progress for Q3 2025, highlighting the anticipated launch of ZEVASKYN and its growing patient demand [1][2][3] Financial Performance - As of September 30, 2025, the company had $207.5 million in cash, cash equivalents, restricted cash, and short-term investments, which is expected to fund operations for over two years [3][6] - R&D spending for Q3 2025 was $4.2 million, a decrease from $8.9 million in Q3 2024, primarily due to costs capitalized into inventory [7] - SG&A expenses increased to $19.3 million in Q3 2025 from $6.4 million in Q3 2024, reflecting increased headcount and costs associated with the ZEVASKYN launch [7] - The net loss for Q3 2025 was $(5.2) million, or $(0.10) per share, compared to a net loss of $(30.3) million, or $(0.63) per share, in Q3 2024 [8][14] Product Development and Launch - The launch of ZEVASKYN has been scaled to meet patient needs, with the first anticipated patient treatment shifted to Q4 2025 due to an optimized release assay [2][4] - Patient demand for ZEVASKYN has more than doubled, with approximately 30 eligible patients identified at the first two Qualified Treatment Centers (QTCs) [4] - The company has activated three QTCs, including Children's Hospital Colorado, and is onboarding additional centers across the U.S. [4] - Coverage decisions from major commercial health plans have been made, covering approximately 60% of all RDEB patients, indicating early market acceptance [4] Strategic Initiatives - The pipeline program ABO-503 has been selected for the FDA Rare Disease Endpoint Advancement Pilot Program, enhancing communication and collaboration with the FDA [2][5] - The management team has been strengthened with the appointment of James A. Gow, MD, as Senior Vice President, Head of Clinical Development & Medical Affairs [5] Balance Sheet Highlights - Total assets as of September 30, 2025, were $231.1 million, up from $108.9 million as of December 31, 2024 [16][17] - Current liabilities totaled $22.2 million, with total liabilities at $59.9 million [16][17]

Core Insights - Abeona Therapeutics has received a permanent HCPCS J-code for its gene therapy ZEVASKYN, which will enhance reimbursement processes and patient access starting January 1, 2026 [1][2] Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [7] - ZEVASKYN (prademagene zamikeracel) is the first and only autologous cell sheet-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [3][4] Product Details - ZEVASKYN is designed to treat wounds in adult and pediatric patients suffering from RDEB, a severe skin disease caused by defects in the COL7A1 gene [3][4] - The therapy involves inserting the correct COL7A1 gene into a patient's skin cells ex vivo, leading to the production of functional type VII collagen [3] - Clinical results indicate that ZEVASKYN provides meaningful wound healing and pain reduction with a single application [3] Regulatory and Market Impact - The assignment of a unique J-code by CMS is expected to simplify claims and reimbursement processing, thereby supporting hospital adoption and patient access for ZEVASKYN [2] - J-codes are crucial for identifying non-orally administered medications in healthcare settings, streamlining medical billing and reimbursement processes [2]

Core Insights - Abeona Therapeutics Inc. has appointed Dr. James A. Gow as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately [1][2] - Dr. Gow brings over 20 years of experience in clinical development and medical affairs, with a focus on gene therapy, particularly in ophthalmology [2] - The company is advancing its pipeline of cell and gene therapies for serious diseases, including its lead product ZEVASKYN, which is the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa [3] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [3] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [3] - Abeona's development portfolio includes adeno-associated virus (AAV)-based gene therapies targeting ophthalmic diseases with significant unmet medical needs [3]

Core Insights - Abeona Therapeutics' ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected for the FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program, which aims to enhance communication and collaboration with the FDA to expedite the development of rare disease therapies [1][2][3] Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa [5] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of its therapies [5] Industry Context - The RDEA Pilot Program, launched by the FDA, supports the development of novel efficacy endpoints for rare disease treatments, allowing for up to three proposals per year from sponsors [3] - XLRS is a rare, monogenic retinal disease with an estimated incidence of 1 in 5,000 to 1 in 20,000 in males, affecting approximately 35,000 individuals in the U.S. and Europe combined, with no approved disease-modifying therapies currently available [4]